Intellective Bio's Commercial Production Project Approved-Newsroom

On 26 January 2025, the National Medical Products Administration (NMPA) approved the marketing application in China for Yinuoqin^® (Esupaglutide Alfa Injection) – a self-developed medicine by Intellective Bio's partner Innogen – for the treatment of adults with Type 2 Diabetes (T2D). 

This represents a new generation of fully human, ultra-long-acting GLP-1 receptor agonists globally! It is expected to open a new chapter in metabolic health management in China, helping diabetic patients achieve faster glycaemic control, potential metabolic improvements, possible weight loss and cardiovascular benefits, all without the need for titration and with convenient administration.

This also marks the second commercial project for which Intellective Bio has supported its partner in successfully obtaining marketing authorisation, signifying that Intellective Bio's commercial journey is firmly on track. To date, Intellective Bio has advanced a total of 13 late-stage projects in its pipeline.

About Innogen

Innogen is the first company in Asia and the third globally to advance an original human long-acting GLP-1 receptor agonist into the drug registration and approval stage. Our core product, Efsubaglutide α (brand name: Yinuoqing®), has entered the commercial phase.As a science-driven and innovation-oriented biopharmaceutical company, Innogen is at the forefront of developing novel therapies for diabetes and other metabolic diseases. With fully integrated, end-to-end capabilities in research, manufacturing, and commercialization, we are committed to becoming a global leader in the field of metabolic disease therapeutics.

Dr. Qinghua Wang, Innogen’s founder, Chairman, and CEO, is also the inventor of Efsubaglutide α. He is a nationally recognized expert and served as Chief Scientist for China’s “Major New Drug Innovation” program under the 13th Five-Year National Science and Technology Plan.

Yinuoqing® (Efsubaglutide α Injection) is a prescription medication and should be obtained through legitimate channels with a prescription from a licensed physician or other qualified healthcare professional. It must be used safely and appropriately under the guidance of physicians, pharmacists, or other certified medical personnel.